Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RFS 2000 in Glioblastoma Multiforme
NCT00005826Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2000
- Primary completion
- Sep 2000
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of rubitecan in glioblastoma multiforme (GBM), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Overall Response Rate, Duration of Response and 2 more. Started Mar 2000; status: completed.
02
Drugs
rubitecan
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00005826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005826.